Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody

International Journal of Pharmaceutics

Volumn 444, Issue 1-2, 2013, Pages 185-192

  Abuqayyas, Lubna ^a   Zhang, Xiaoyan ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anti platelet antibody; Fc receptors; IgG; Pharmacodynamics; Pharmacokinetics; Tissue disposition

Indexed keywords

ANTITHROMBOCYTIC AGENT; FC RECEPTOR; MWREG30; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET MEMBRANE GLYCOPROTEIN IIB; RECEPTORS, IGG; THROMBOCYTOPENIA; TISSUE DISTRIBUTION;

EID: 84874339908     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.01.001     Document Type: Article

References (34)

1. L. Abuqayyas, and J.P. Balthasar Application of knockout mouse models to investigate the influence of FcR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody Int. J. Pharmaceut. 439 2012 8 16
2. S. Amigorena, and C. Bonnerot Fc receptor signaling and trafficking: a connection for antigen processing Immunol. Rev. 172 1999 279 284
3. S. Amigorena, and C. Bonnerot Fc receptors for IgG and antigen presentation on MHC class I and class II molecules Semin. Immunol. 11 1999 385 390
4. O. Berlanga, N. Emambokus, and J. Frampton GPIIb (CD41) integrin is expressed on mast cells and influences their adhesion properties Exp. Hematol. 33 2005 403 412
5. A. Bhatia, S. Blades, G. Cambridge, and J.C. Edwards Differential distribution of Fc gamma RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments Immunology 94 1998 56 63
6. D. Bordessoule, M. Jones, K.C. Gatter, and D.Y. Mason Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67 Br. J. Haematol. 83 1993 370 383
7. D.L. Cassel, M.A. Keller, S. Surrey, E. Schwartz, A.D. Schreiber, E.F. Rappaport, and S.E. McKenzie Differential expression of Fc gamma RIIA, Fc gamma RIIB and Fc gamma RIIC in hematopoietic cells: analysis of transcripts Mol. Immunol. 30 1993 451 460
8. J. Chaparro-Riggers, H. Liang, R.M. Devay, L. Bai, J.E. Sutton, W. Chen, T. Geng, K. Lindquist, M.G. Casas, L.M. Boustany, C.L. Brown, J. Chabot, B. Gomes, P. Garzone, A. Rossi, P. Strop, D. Shelton, J. Pons, and A. Rajpal Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 J. Biol. Chem. 287 2012 11090 11097
9. D.B. Cines, and V.S. Blanchette Immune thrombocytopenic purpura N. Engl. J. Med. 346 2002 995 1008
10. R. Deng, and J.P. Balthasar Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia J. Pharm. Sci. 96 2007 1625 1637
11. A. Garg, and J.P. Balthasar Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice J. Pharmacokinet. Pharmacodyn. 34 2007 687 709
12. J.E. Gessner, H. Heiken, A. Tamm, and R.E. Schmidt The IgG Fc receptor family Ann. Hematol. 76 1998 231 248
13. T. Igawa, S. Ishii, T. Tachibana, A. Maeda, Y. Higuchi, S. Shimaoka, C. Moriyama, T. Watanabe, R. Takubo, Y. Doi, T. Wakabayashi, A. Hayasaka, S. Kadono, T. Miyazaki, K. Haraya, Y. Sekimori, T. Kojima, Y. Nabuchi, Y. Aso, Y. Kawabe, and K. Hattori Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat. Biotechnol. 28 2010 1203 1207
14. E. Ivan, and A.I. Colovai Human Fc receptors: critical targets in the treatment of autoimmune diseases and transplant rejections Hum. Immunol. 67 2006 479 491
15. R.P. Junghans, and C.L. Anderson The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor Proc. Natl. Acad. Sci. U.S.A. 93 1996 5512 5516
16. E.D. Lobo, R.J. Hansen, and J.P. Balthasar Antibody pharmacokinetics and pharmacodynamics J. Pharm. Sci. 93 2004 2645 2668
17. C.F. McDonagh, K.M. Kim, E. Turcott, L.L. Brown, L. Westendorf, T. Feist, D. Sussman, I. Stone, M. Anderson, J. Miyamoto, R. Lyon, S.C. Alley, H.P. Gerber, and P.J. Carter Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther. 7 2008 2913 2923
18. D.R. Mould, and B. Green Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development BioDrugs 24 2010 23 39
19. F. Nimmerjahn, P. Bruhns, K. Horiuchi, and J.V. Ravetch FcgammaRIV: a novel FcR with distinct IgG subclass specificity Immunity 23 2005 41 51
20. F. Nimmerjahn, and J.V. Ravetch Fcgamma receptors: old friends and new family members Immunity 24 2006 19 28
21. F. Nimmerjahn, and J.V. Ravetch Fcgamma receptors as regulators of immune responses Nat. Rev. Immunol. 8 2008 34 47
22. S. Nishio, T. Yamamoto, K. Kaneko, N. Tanaka-Matsumoto, S. Muraoka, M. Kaburaki, Y. Kusunoki, K. Takagi, and S. Kawai Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab Mod. Rheumatol. 19 2009 329 333
23. J.V. Ravetch, and S. Bolland IgG Fc receptors Annu. Rev. Immunol. 19 2001 275 290
24. S. Siberil, C.A. Dutertre, W.H. Fridman, and J.L. Teillaud FcgammaR: the key to optimize therapeutic antibodies? Crit. Rev. Oncol. Hematol. 62 2007 26 33
25. D. Soligo, G. Cattoretti, M. Colombi, N. Polli, F. Capsoni, F. Rilke, and G.L. Deliliers Bone marrow and tissue expression of gpIIb/IIIa, LFA-1, Mac-1 and gp150,95 glycoproteins Eur. J. Haematol. 42 1989 173 181
26. M. Tabrizi, G.G. Bornstein, and H. Suria Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease AAPS J. 12 2010 33 43
27. M.A. Tabrizi, C.M. Tseng, and L.K. Roskos Elimination mechanisms of therapeutic monoclonal antibodies Drug Discov. Today 11 2006 81 88
28. T. Takai, M. Li, D. Sylvestre, R. Clynes, and J.V. Ravetch FcR gamma chain deletion results in pleiotrophic effector cell defects Cell 76 1994 519 529
29. T. Tarasenko, J.A. Dean, and S. Bolland FcgammaRIIB as a modulator of autoimmune disease susceptibility Autoimmunity 40 2007 409 417
30. W.B. Tuijnman, D.F. Van Wichen, and H.J. Schuurman Tissue distribution of human IgG Fc receptors CD16, CD32 and CD64: an immunohistochemical study APMIS 101 1993 319 329
31. J.G. Van de Winkel, and P.J. Capel Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications Immunol. Today 14 1993 215 221
32. E.F. Van Leeuwen, J.T. Van der Ven, C.P. Engelfriet, and A.E. Von Dem Borne Specificity of autoantibodies in autoimmune thrombocytopenia Blood 59 1982 23 26
33. W. Wang, E.Q. Wang, and J.P. Balthasar Monoclonal antibody pharmacokinetics and pharmacodynamics Clin. Pharmacol. Ther. 84 2008 548 558
34. L.S. Zuckier, L. Georgescu, C.J. Chang, M.D. Scharff, and S.L. Morrison The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G Cancer 73 1994 794 799